12-month data confirming that L-130 is the first reported stable oral psilocin First-in-Man clinical data demonstrates the superior PK profile of L-130 2023 sales of $1.1M (CAD) for Altemia®VANCOUVER, British Columbia--(BUSINESS WIRE)--Lobe Sciences Ltd
WINNIPEG, Manitoba--(BUSINESS WIRE)--Farmers Edge Inc. (“Farmers Edge” or the “Company”) (TSX: FDGE) today announced that it has received a revised non-binding proposal from its majority shareholder, Fairfax Financial Holdings Limited (“Fairfax
TOKUSHIMA, Japan--(BUSINESS WIRE)--Following the previous information on June 30th in 2023, we are excited to share our latest development status. A Phase III study of DFP-10917 in patients with recurrent or refractory acute myeloid leukemia (R/R AML) at
Preliminary unaudited total net revenue for the fourth quarter and full year 2023 of approximately $45 million and $176 million Preliminary unaudited net product revenue for the fourth quarter and full year 2023 of approximately $42 million and $159 mill
- Following EMA, FDA accepted BLA for DMB-3115SEOUL, South Korea--(BUSINESS WIRE)--#AccordBiopharma--Dong-A ST (President/CEO Min-young Kim, KRX:170900) announced that Accord BioPharma, Inc., a subsidiary of Intas Pharmaceuticals Ltd, in the United State
OTTAWA, Ontario--(BUSINESS WIRE)--#AAV--Virica Biotech Inc. (“Virica”), a leading developer of cell enhancers for scaling of viral vectors, as well as cell and gene therapies, announced today the expansion of their sales team along with a full present
- Recently announced positive Phase 2 topline data in Major Depressive Disorder (“MDD”) with 79% of patients in remission from depression after two doses of CYB003 (12mg) - - Programs supported by robust intellectual property portfolio with 40 grante
TORONTO--(BUSINESS WIRE)--Sagard Healthcare – a biopharmaceutical royalty and credit investor – today announced several developments and milestones for the strategy, including the closing of a $250 million permanent credit facility and the completion
VANCOUVER, British Columbia--(BUSINESS WIRE)--#JPM24--Aspect Biosystems, a biotechnology company pioneering the development of bioprinted tissue therapeutics to transform the treatment of disease, today announced that Founder and CEO Tamer Mohamed will pr
- Advancing industry-leading antimyostatin pipeline, comprised of multiple, novel assets with unparalleled selectivity, to treat spinal muscular atrophy (SMA) and cardiometabolic disorders - Completed enrollment for apitegromab pivotal Phase 3 SAPPHIRE t
Sign up for one of BAM's newsletter to learn more about bioscience, happenings in Manitoba's bioeconomy, industry conferences, and BAM training events.